Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q1 2022 · 10-Q
Revenue—
Net Income-$689.50K-$689.50KN/M vs Q1 2021 EPS, diluted—
Operating Income-$689,499N/M Operating Cash Flow-$860,779N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 13, 2022 · 43 d after period end